Cargando…

Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines

This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. Although much commoner in the eastern hemisphere, with an age-standardised incidence rate of 0.39 per 100 000 population, cancers of the nasopharynx form one of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Simo, R, Robinson, M, Lei, M, Sibtain, A, Hickey, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873914/
https://www.ncbi.nlm.nih.gov/pubmed/27841121
http://dx.doi.org/10.1017/S0022215116000517
_version_ 1782432965549096960
author Simo, R
Robinson, M
Lei, M
Sibtain, A
Hickey, S
author_facet Simo, R
Robinson, M
Lei, M
Sibtain, A
Hickey, S
author_sort Simo, R
collection PubMed
description This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. Although much commoner in the eastern hemisphere, with an age-standardised incidence rate of 0.39 per 100 000 population, cancers of the nasopharynx form one of the rarer subsites in the head and neck.(1) This paper provides recommendations on the work up and management of nasopharyngeal cancer based on the existing evidence base for this condition. RECOMMENDATIONS: • Patients with nasopharyngeal carcinoma (NPC) should be assessed with rigid and fibre-optic nasendoscopy. (R) • Nasopharyngeal biopsies should be preferably carried out endoscopically. (R) • Multislice computed tomographic (CT) scan of head, neck and chest should be carried out in all patients and magnetic resonance imaging (MRI) where appropriate to optimise staging. (R) • Radiotherapy (RT) is the mainstay for the radical treatment for NPC. (R) • Concurrent chemoradiotherapy offers significant improvement in overall survival in stage III and IV diseases. (R) • Surgery should only be used to obtain tissue for diagnosis and to deal with otitis media with effusion. (R) • Radiation therapy is the treatment of choice for stage I and II disease. (R) • Intensity modulated radiation therapy techniques should be employed. (R) • Concurrent chemotherapy with radiation therapy is the treatment of choice for stage III and IV disease. (R) • Patients with NPC should be followed-up and assessed with rigid and/or fibre-optic nasendoscopy. (G) • Positron emission tomography–computed tomography (PET–CT), CT or MRI scan should be carried out at three months from completion of treatment to assess response. (R) • Multislice CT scan of head, neck and chest should be carried out in all patients and MRI scan whenever possible and specially in advanced cases with suspected recurrence. (R) • Surgery in form of nasopharyngectomy should be considered as a first line treatment of residual or recurrent disease at the primary site. (R) • Neck dissection remains the treatment of choice for residual or metastatic neck disease whenever possible. (R) • Re-irradiation should be considered as a second line of treatment in recurrent disease. (R)
format Online
Article
Text
id pubmed-4873914
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-48739142016-05-27 Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines Simo, R Robinson, M Lei, M Sibtain, A Hickey, S J Laryngol Otol Guidelines This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. Although much commoner in the eastern hemisphere, with an age-standardised incidence rate of 0.39 per 100 000 population, cancers of the nasopharynx form one of the rarer subsites in the head and neck.(1) This paper provides recommendations on the work up and management of nasopharyngeal cancer based on the existing evidence base for this condition. RECOMMENDATIONS: • Patients with nasopharyngeal carcinoma (NPC) should be assessed with rigid and fibre-optic nasendoscopy. (R) • Nasopharyngeal biopsies should be preferably carried out endoscopically. (R) • Multislice computed tomographic (CT) scan of head, neck and chest should be carried out in all patients and magnetic resonance imaging (MRI) where appropriate to optimise staging. (R) • Radiotherapy (RT) is the mainstay for the radical treatment for NPC. (R) • Concurrent chemoradiotherapy offers significant improvement in overall survival in stage III and IV diseases. (R) • Surgery should only be used to obtain tissue for diagnosis and to deal with otitis media with effusion. (R) • Radiation therapy is the treatment of choice for stage I and II disease. (R) • Intensity modulated radiation therapy techniques should be employed. (R) • Concurrent chemotherapy with radiation therapy is the treatment of choice for stage III and IV disease. (R) • Patients with NPC should be followed-up and assessed with rigid and/or fibre-optic nasendoscopy. (G) • Positron emission tomography–computed tomography (PET–CT), CT or MRI scan should be carried out at three months from completion of treatment to assess response. (R) • Multislice CT scan of head, neck and chest should be carried out in all patients and MRI scan whenever possible and specially in advanced cases with suspected recurrence. (R) • Surgery in form of nasopharyngectomy should be considered as a first line treatment of residual or recurrent disease at the primary site. (R) • Neck dissection remains the treatment of choice for residual or metastatic neck disease whenever possible. (R) • Re-irradiation should be considered as a second line of treatment in recurrent disease. (R) Cambridge University Press 2016-05 /pmc/articles/PMC4873914/ /pubmed/27841121 http://dx.doi.org/10.1017/S0022215116000517 Text en © JLO (1984) Limited 2016 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Guidelines
Simo, R
Robinson, M
Lei, M
Sibtain, A
Hickey, S
Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines
title Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines
title_full Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines
title_fullStr Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines
title_full_unstemmed Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines
title_short Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines
title_sort nasopharyngeal carcinoma: united kingdom national multidisciplinary guidelines
topic Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873914/
https://www.ncbi.nlm.nih.gov/pubmed/27841121
http://dx.doi.org/10.1017/S0022215116000517
work_keys_str_mv AT simor nasopharyngealcarcinomaunitedkingdomnationalmultidisciplinaryguidelines
AT robinsonm nasopharyngealcarcinomaunitedkingdomnationalmultidisciplinaryguidelines
AT leim nasopharyngealcarcinomaunitedkingdomnationalmultidisciplinaryguidelines
AT sibtaina nasopharyngealcarcinomaunitedkingdomnationalmultidisciplinaryguidelines
AT hickeys nasopharyngealcarcinomaunitedkingdomnationalmultidisciplinaryguidelines